



April 25, 2024  
JCR Pharmaceuticals Co., Ltd.

Translation

**Notice Regarding Nomination of a Candidate to the Board of Director**

April 25, 2024 -- [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552: Chairman and President Shin Ashida, “JCR”) announced that the Board of Directors meeting held today resolved a proposal regarding nomination of a candidate for its Board of Director to be presented before JCR’s Ordinary General Meeting of Shareholders scheduled in June 2024.

The appointment of a new member of the Board will be subject to approval at the Ordinary General Meeting of Shareholders.

1. Candidate for New Director

Name	Andrea Hebe Spezzi, MD, FFPM	
Career	Jun. 1994	Consultant Paediatrician/Staff Grade Paediatrician, Princess Alexandra Hospital, Saint Jamue Hospital, Pedro de Elizalde Children’s Hospital
	Mar. 2003	Research Physician Hammersmith Medicines Research
	Nov. 2004	Global Medical Director Takeda Global R&D
	Jul. 2009	Vice President R&D, Medicines Development Leader Rare Diseases, GlaxoSmithKline, Rare Diseases Business Unit
	Sep. 2015	Founded Andrea Spezzi Executive Consultant (current post)
	Jan. 2016	Co-founder and Chief Medical Office, Orchard Therapeutics
	Jun. 2021	Independent Board Director, Bloomsbury Genetic Therapies (current post)
	Sep. 2021	Co-Founder, President and CEO/Board Executive Director, Rejuvitas Inc
	Sep. 2023	Discovery Ventures Healthcare Fund Advisor and acting Partner (current post)
	Dec. 2023	Global Strategic Adviser, JCR Pharmaceuticals Co., Ltd.(current post)

## 2. Retiring Directors

Mathias Schmidt, PD, Ph.D. (current position: Vice President, Patient Association Response, Business development and IR fields, excluding Japan, ArmaGen Inc., CEO, JCR USA Inc. CEO)

Dr. Schmidt will be appointed “Executive Fellow and ArmaGen Inc. CEO” at a Board Meeting as scheduled in June, 2024.

Toshihiro Ishikiriya (current position: Outside director)

Mr. Ishikiriya will be appointed “Senior Executive Fellow” at a Board Meeting as scheduled in June, 2024.

### <Reference>

Board of Directors after the Ordinary General Meeting of Shareholders and the Board of Directors meeting to be held in June 2024. (planned)

Title*	Name	Area of Supervision
Representative Director, Chairman, President	Shin Ashida	
Director, Senior Managing Executive Officer	Toru Ashida	Sales, Executive Director, Sales Division
Director, Senior Managing Executive Officer	Hiroyuki Sonoda, Ph.D.	Research, Executive Director, Research Division
Director, Managing Executive Officer	Yoshio Hiyama, Ph.D.	Quality Assurance, Executive Director, Quality Assurance Division and Director, Regulatory Affairs Department
Director, Managing Executive Officer	Andrea Hebe Spezzi, MD, FFPM	Clinical Development,
Director (Outside)	Takashi Suetsuna	
Director (Outside)	Toshihide Yoda	
Director (Outside)	Yuko Hayashi, Ph.D.	
Director (Outside)	Yutaka Atomi, M.D., Ph.D.	
Director (Outside)	Philippe Fauchet, OBE	
Director (Outside)	Marc Dunoyer	

\*The Executive Officer System will be transitioned to the new system after the Board of Directors meeting in June.

### **About JCR Pharmaceuticals Co., Ltd.**

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-

Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

### **Cautionary Statement Regarding Forward-Looking Statements**

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.*

*Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

#### Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jp.jcrpharm.com](mailto:ir-info@jp.jcrpharm.com)

###